TMDX vs. GKOS, STVN, BLCO, INSP, NARI, PRCT, NVST, NVCR, IRTC, and LIVN
Should you be buying TransMedics Group stock or one of its competitors? The main competitors of TransMedics Group include Glaukos (GKOS), Stevanato Group (STVN), Bausch + Lomb (BLCO), Inspire Medical Systems (INSP), Inari Medical (NARI), PROCEPT BioRobotics (PRCT), Envista (NVST), NovoCure (NVCR), iRhythm Technologies (IRTC), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.
TransMedics Group vs.
Glaukos (NYSE:GKOS) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, community ranking, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.
Glaukos has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500.
Glaukos currently has a consensus target price of $147.75, indicating a potential downside of 5.65%. TransMedics Group has a consensus target price of $122.70, indicating a potential upside of 114.51%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than Glaukos.
TransMedics Group has a net margin of 8.14% compared to Glaukos' net margin of -42.43%. TransMedics Group's return on equity of 18.74% beat Glaukos' return on equity.
99.0% of Glaukos shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 6.4% of Glaukos shares are owned by insiders. Comparatively, 7.0% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, TransMedics Group had 29 more articles in the media than Glaukos. MarketBeat recorded 35 mentions for TransMedics Group and 6 mentions for Glaukos. Glaukos' average media sentiment score of 0.59 beat TransMedics Group's score of 0.18 indicating that Glaukos is being referred to more favorably in the media.
Glaukos received 335 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 64.83% of users gave Glaukos an outperform vote while only 59.36% of users gave TransMedics Group an outperform vote.
Summary
TransMedics Group beats Glaukos on 12 of the 18 factors compared between the two stocks.
Get TransMedics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for TMDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TransMedics Group Competitors List
Related Companies and Tools
This page (NASDAQ:TMDX) was last updated on 1/18/2025 by MarketBeat.com Staff
